Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact

News

Feb 6, 2025Blog | Member News, Healthcare

FDA approves Vertex Pharmaceuticals’ new non-opioid painkiller

Boston Globe

New England Council member, Vertex Pharmaceuticals, announced that Journavx, a non-opioid painkiller, has been approved by the U.S. Food and Drug Administration (FDA). The biotech company has invested in developing a non-opioid pain medicine for over 20 years, aiming to address the nation’s opioid crisis and offer a pain relief option without the risk of addiction.

The FDA approved the pill to treat adults with moderate-to-severe acute pain. It works by blocking pain signals only found in the peripheral pain-sensing neurons, not in the brain, thus providing effective pain relief without the addictive potential of opioids. As this is a prescription medicine, patients should always go to their healthcare provider for medical advice about treatments first. Vertex has established patient support programs to help ensure that patients can access information and consultation about Journavx.

“Today’s approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With the approval of Journavx, . . . we have the opportunity to change the paradigm of acute pain management and establish a new standard of care.”

The New England Council commends Vertex Pharmaceuticals for this important milestone for public health.

Read more via the Boston Globe and Vertex Press.

Council Related News
Read Article Blog | Member News, Higher Education

University of New England joins global entrepreneurship network

Read Article Blog | Member News, Higher Education

Framingham State University museum receives largest donation in 50-year history

Read Article Blog | Member News, Healthcare

Point32Health hires new CEO

Read Article Blog | Member News, Healthcare

Dana-Farber plans to hire 700 new nurses

Read Article Blog | Member News, Transportation & Infrastructure

Massachusetts Port Authority is pushing to make MA a hub for sustainable aviation fuels

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit